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INTRODUCTION 
 
 
 Systemic Lupus Erythematosus (SLE), more a syndrome than a disease, is the  
 
prototype of immune complex mediated systemic autoimmune diseases. A prevalence  
 
study in India showed a crude incidence rate of 4 per 100,000 population per year1. It has  
 
been diagnosed in 1.5 million people in the United States. Women have a much higher  
 
risk of developing SLE, and the woman-to-man ratio is about 10-15:12. Racial differences  
 
are present and it is seen that women of black, Hispanic, Asian, and Native American  
 
backgrounds are more frequently affected than their white peers3. 
 
SLE, though a disease known for over half a century, still carries a grim  
 
prognosis. More than half of these patients develop irreversible organ damage over time1.  
 
Lupus nephritis occurs in about half of SLE patients in India as per published series  
 
reporting between 35-73% occurrences 4-9. Renal involvement in SLE occurs early in the  
 
disease and is usually within 10 years of the appearance of SLE10. Studies have suggested  
 
that male lupus nephritis patients have more severe disease than their female  
 
counterparts10. Lupus nephritis is seen more in Asians, African-Caribbeans and African- 
 
Americans10. In a retrospective study published in 1988 by McCune et al, male sex,  
 
young age (<33years), and non-European ancestry were determinants of earlier renal  
 
involvement in SLE patients11. 
  
With modern treatment, the survival of SLE patients have improved in the west to  
 
about  80% at 10 years after diagnosis12 but, the figures for the Asian Indians are not so  
 
good. Murali et al in a study of 98 patients between 1981 and 1993 showed 50%-60%  
 
survival of SLE patients at 10 years13,14. It is a therapeutic challenge to treat lupus  
 
nephritis, since early intervention can dramatically change the disease course.  
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Unfortunately, thirty or more years ago, patients with severe Class  IV nephritis surviving  
 
for more than a year or two were few, and at least 50% of those with less severe form of  
 
nephritis used to die within 5 years15. It is really heartening to see that Cyclophosphamide  
 
introduction into the treatment of lupus nephritis 20 years later made a significant impact  
 
on prognosis and  renal involvement no longer affects the survival rates of these  
 
patients16.  
  
While studies on SLE in India have been previously published, there has been a  
 
paucity of data with regards to prognostic factors and clinical outcomes in lupus nephritis  
 
patients, which constitutes a major subset of severe SLE patients. A study done by  
 
Abraham et al in 1987-1999, looked at the prognostic factors in class IV lupus nephritis  
 
over 50 months. In the present decade, with newer drugs in the armamentarium, has there  
 
been a change in the general outlook of this disease as compared to the west? Are the  
 
prognostic factors different in our population?  
  
We endeavour to fill these lacunae in our present understanding of the clinical  
 
presentation and outcome of the disease in our population.  
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LITERATURE REVIEW 
 
  
 Systemic Lupus Erythematosus (SLE) is a classic model of immune complex 
mediated disease. Its expression and clinical course varies from the very mild, with 
arthralgias and skin rashes, to life threatening features, when it affects renal and central 
nervous system. 
Coexistence and evolution into other autoimmune disorders can also occur. 
Diagnosis Of SLE 
 
 The American College of Rheumatology has a criteria for the classification of  
 
patients as  having SLE17. If a patient has, at any time in his or her medical history, 4  
 
of the 11 criteria documented, the diagnosis of SLE can be made with about 95%  
 
specificity and 85% sensitivity. These criteria are actually meant for epidemiological  
 
purposes to ensure that SLE patients reported in the literature do in fact have the disease  
 
and not for bedside diagnosis of an individual patient. The diagnosis of  SLE is based on  
 
clinical judgement and supportive laboratory evidence. SLE can be suspected whenever 2  
 
or more organ systems listed in ACR criteria are involved1.  
 
Epidemiology Of Systemic Lupus Erythematosus 
A prevalence study in India (carried out in a rural population near Delhi) by 
Malaviya et al published in 1993 surveyed a population of 91,888 and found a point 
prevalence of 3 per 100,000 (95%CI= 0-6.86 per 100,000)18. This is a much lower figure 
than reported from the west. Various studies have shown prevalence to be about 12.5 per 
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100, 000 adults in England 19 to 39 per 100,000 in Finland 20 and 124 per 100,000 in 
USA21. Any large hospital in India, do encounter a good number of SLE cases1. The 
Copcord Bhigwan, a prospective study from Pune, has found a crude incidence rate of 1 
per 25,000 person years i.e. 4 per 100,000 population per year1. 
SLE occurs three times more commonly in females than in males among children.  
Between puberty and the fourth decade of life, the female to male ratio is 9:1 and the 
incidence is 60%. The ratio reverts back to 3:1 in the older age groups22. 
The annual incidence of SLE in the African Carribean blacks which is the race 
that is maximally affected, ranges from six to 35 new cases per 100,000 population in 
relatively low-risk to high-risk groups22. 
Presenting Signs and Symptoms Of SLE 
80% of patients with SLE will present with involvement of the skin or joints. 
They may also present with fever accompanied by single organ involvement, such as 
inflammatory serositis, glomerulonephritis, neuropsychiatric disturbance or 
hematological disorder. On the other hand, patients present with severe, generalized acute 
lupus crisis with multiorgan involvement 2. 
There are regional variations in clinical features reported from different parts of 
India4-9. Raynaud’s phenomenon is almost absent in patients from Southern India 
whereas lymphadenopathy occurs more often4-9. Also low frequency of neuropsychiatric 
manifestations at onset in Northern India has been noted. On follow up, there was lower 
frequency of photosensitivity and neuropsychiatric manifestations in Western India, 
lower frequency of nephritis in Central India and the rarity of Raynaud’s in Southern 
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India in comparison to other parts of the country4-9. But these studies are hospital based 
studies and hence could have confounding variables. 
Evaluation of disease activity and severity 
A number of validated indices are available for quantifying disease activity. The  
 
more popular indices include- BILAG 23, SLEDAI 24, SLAM 25 and LAI 26. These help  
 
in formulating the overall treatment plan and assessment of prognosis. The details of  
 
SLEDAI activity index is shown in (Annexure A). In our study SLEDAI index has been  
 
used as a measure of disease activity. A valid measure of damage in patients with lupus is  
 
the SLICC/ ACR Damage Index (DI)27. 
 
Definition Of Lupus Nephritis(LN) 
  
One of the following must be present: 1. a renal biopsy showing mesangial, focal  
 
proliferative, or membranous lupus nephritis; 2. a 30% decline in creatinine clearance  
 
over a 1 year period; 3. greater than 1G urine protein in a 24-hour urine specimen. If none  
 
of these features are present, at least three of the following are required in a 12 month  
 
period: 1. s.albumin of <3g/dl; 2. 2 to 4+ proteinuria; 3. oval fat bodies; granular,  
 
hyaline, or red cell casts in the urine; 4. persistent haematuria or greater than five red  
 
cells per high power field in the urine. Finally, other etiologies of genitourinary disease  
 
(e.g., diabetes, hypertension, drug- induced nephropathies, infection) must be  
 
excluded 12. 
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Epidemiology Of Lupus Nephritis 
Renal involvement in systemic lupus erythematosus (SLE) is quite common and 
is a strong predictor of poor outcome. Eight large cohort studies consisting of 2649 SLE 
patients, showed that the prevalence varied from 31 to 65%12. A Study done at the Johns 
Hopkins Medical Center between 1992-94, analyzed the annual incidence of nephritis in 
384 lupus patients. The one year incidence of acute renal disease was 10%22. Lupus 
nephritis occurs in about half of SLE patients (range 35%-73%) in India1. 
 A retrospective study published in 1986 evaluated 107 active lupus nephritis 
patients over a median follow up of seven years and found that male sex, young age 
(<33years), and non-European ancestry were determinants of earlier renal involvement in 
SLE patients16. 
Etiology Of Systemic Lupus Erythematosus And Lupus Nephritis 
 
The etiology of SLE is multifactorial. Disordered immune response could be 
triggered by genetic predisposition, sex hormones, and environmental insults22. 
Among the HLA antigens, HLA-DR2 and HLA-B8 are more associated with the 
development of lupus renal disease23-25. Polymorphisms of Fc receptors for IgG (Fc 
gammaR) have been recently identified as a risk factor, implicating defective handling of 
circulating immune complexes in the development of renal disease28. Heredity does play 
a role, shown by a concordance rate of 25 and 60% among monozygotic twins. The 
polygenic nature and the contribution of environmental factors are suggested by the 
moderate concordance rate22. 
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Immunopathogenesis Of Lupus Nephritis 
 There are at least three immuno-pathogenic mechanisms supported by 
experimental data29. First, circulating immune complexes consisting chiefly of DNA and 
anti-DNA are deposited in the kidney. Local inflammatory process occur due to resultant 
complement activation and chemotaxis of neutrophils29. Nucleosomes, the fundamental 
unit of chromatin, are the target and mediators of antibody-related glomerular immune-
complex deposition29. The nucleosome is released by internucleosomal cleavage by 
endonucleases activated during cell apoptosis and consists of a core composed of an 
octamer of two copies each of Histones H2A, H2B, H3 and H4, around which is wrapped 
a stretch of helical DNA, approximately 150bp in length29 (figure 1). Antibodies reactive 
to nucleosomes have been detected both in patients with lupus and murine models even 
prior to the development of anti-dsDNA and anti-histone antibodies. These antibodies are 
IgG in isotype and usually are of IgG2a and IgG2b in subclass consistent with a T-cell 
mediated antigen driven response29 (figure 2). 
  Second mechanism is by in situ formation of antigen and antibody complexes 
leading to complement activation and leukocyte-mediated injury. Thirdly, antibodies 
against specific cellular targets produce renal injury. For example, antibodies, such as 
anti-ribosomal P, bind to cytoplasmic antigens that have been translocated to the cell 
membrane with subsequent penetration and disruption of cellular function29.  
An additional mechanism is seen in SLE patients with the antiphospholipid 
antibody syndrome. Glomerular thrombosis can result from the hypercoagulability that  
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Fig 2:Schematic representation of the role of apoptosis 
and nucleosomes in the pathogenesis of SLE 
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accompanies antibodies directed against negatively charged phospholipid-protein 
complexes (e.g. biologic false positive VDRL, anticardiolipin antibodies, and lupus 
anticoagulant)29. 
New PathologicalClassification of Lupus Nephritis 
 
The Renal Pathology Society Working Group and the International Society of  
 
Nephrology Working Group in 2002 approved a new classification of LN (Table 1)30.  
 
This new classification supercedes the modified World Health Organization  
 
(WHO) classification of 1995. Lupus Nephritis involves more than 1 component within  
 
the kidney. In fact, it may extend from the glomeruli to the tubuli, the interstitium, and  
 
the surrounding blood vessels. The renal involvement presents a pleomorphic  
 
morphology and a high variability in glomerular lesions from patient to patient 
 
LN is thus divided into 6 classes according to severity of the lesions observed30 
 
Class I, minimal mesangial LN; 
 
Class II, mesangial proliferative LN; 
 
Class III, focal LN; 
 
Class IV, diffuse segmental LN; 
 
Class V, membranous LN; and 
 
Class VI, advanced sclerosing LN. 
 
As illustrated by Dr. Sheshan31, Class I LN shows normal findings at  light  
 
microscopy, but abnormal immunofluorescence & ultrastructural changes.  
 
Class II  LN is associated with mesangial pathology and may be associated with necrosis  
 
of cells in the capillary walls, of fibrinoid nature, with hyaline thrombi due to an excess  
 
of  immune complexes, with or without proliferative changes.  
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Class III LN is characterized by segmental or global endo/extracapillary proliferation  
 
with active sclerosing lesions with subendothelial deposits.  
 
Class IV is characterized by  > 50% glomerular involvement with pathology similar to  
 
class III, more diffuse with segmental or global lesions. Subendothelial deposits are  
 
very frequent, with infiltration of inflammatory cells and proliferation. Proliferation and  
 
necrosis (with antineutrophil cytoplasmic antibodies related disease) can be segmental  
 
(class IV-S) or global (class IV-G). Differentiation of IV-S from IV G is important from a  
 
prognostic point of view. The majority of class IV cases (65%) are IV G. Class IV-S  
 
cases are characterized by higher hematuria, less proteinuria, fewer deposits, but more  
 
necrosis. In the presence of monocyte infiltration, outcomes are worse.  
 
Class V is called membranous presenting predominantly with nephritic syndrome without  
 
active urinary sediments and it has a higher risk of renal vein thrombosis. 
 
Class VI is associated with > 90% glomerulosclerosis. Characteristic features at  
 
immunofluorescence include deposit of IgG, IgM, and IgA; complement factors C3 and  
 
C1q; and Ig light chains. Activity and chronicity indices are being provided to the  
 
clinician for LN patients, as they represent predictors, although weak, of long-term  
 
prognosis. Such a weakness may be related to the still-lingering interobserver and  
 
intraobserver variations. A value of 1+ corresponds to an involvement of < 25%, 2+  
 
to 25% to 50%, and 3+ to > 50%. As reported by different investigators, negative  
 
prognostic indices include crescents in more  than 30% of the glomeruli, a chronicity  
 
index > 5, male sex, and a higher lesion activity in the glomeruli31. 
 
The association of LN with antiphospholipid antibodies also has a significant  
 
effect on prognosis because it leads more frequently to irreversible organ damage, with  
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destruction of most renal findings, hence, the lack of association with a specific LN  
 
class31. 
 
TABLE 1: NIH RENAL PATHOLOGY SYSTEM  
ACTIVITY INDEX CHRONICITY INDEX 
Glomerular abnormalities  
1. Cellular proliferation 1. Glomerular sclerosis 
2. Fibrinoid necrosis, karyorrhexis 2. Fibrous crescents 
3. Cellular crescents  
4. Hyaline thrombi, wire loops  
5. Leukocyte infiltration  
Tubulointerstitial abnormalities  
1. Mononuclear cell infiltrates 1. Interstitial fibrosis 
 2. Tubular atrophy 
Severity of each index quantitated as 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. 
Fibrinoid necrosis and cellular crescents are weighted by a factor of 2. Maximum activity 
index is 24 and that of chronicity index 12. 
Renal Biopsy 
The strongest argument for a renal biopsy is likelihood that the pathologic 
findings will influence initiation, selection or discontinuation of therapeutic agents. In 
determining the role of renal biopsy in lupus renal disease several points are relevant. 
Although it is possible to infer the WHO class of renal disease by evaluating the 
urinalysis, 24 hour urine protein excretion, and serologies, this is not inviolate. There is 
data correlating WHO Classification and National Institute of Health activity and 
chronicity indices with prognosis and these can be obtained reliably only by a biopsy32. 
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Also membranous lupus nephritis has a different prognosis and treatment than 
proliferative disease32.  
A renal biopsy is indicated when the clinical findings are indeterminate and 
objective evidence of active lupus nephritis is required prior to initiating treatment. A 
biopsy may be required to determine whether cytotoxic therapy is warranted. A biopsy 
may also help distinguish a patient with a high activity but low to moderate chronicity 
index, from a patient with moderate to high chronicity in whom the likelihood of 
reversibility is too small to justify aggressive immunosuppressive therapy32. 
Indications for a renal biopsy in SLE patients’ include32: 
 
Hematuria and proteinuria; 
 
Renal dysfunction; 
 
Hypertension; 
 
Low levels of the complement factor C3; 
 
The presence of chronic renal lesions; and modifications in  
 
therapy: initiation, changes, or discontinuation. 
 
Renal biopsy can provide 3 mainstays of the final diagnosis: classification, extent  
 
of reversibility and chronicity of the renal disease, and outcome prediction. Limitations  
 
are represented by the need to obtain renal  cortical tissue and to collect adequate  
 
specimens, as well as the evaluation of focal lesions with limited sampling of highly  
 
heterogeneous glomerular involvement32. 
 13
 
Management  
The management of lupus renal disease should be based on risk stratification and 
the prognostic information available clinically or by renal biopsy.  
WHO CLASS I: Class I nephritis which is defined by normal histologic findings and 
requires no specific therapy9,10,15.  
WHO CLASS II-MESANGIAL: Class II-A, mesangial lupus nephritis with mesangial 
deposition of immunoglobulin if unaccompanied by proteinuria and active urinary 
sediment does not require treatment. Class II-B, mesangial lupus nephritis when 
accompanied by significant proteinuria (e.g.: greater than 1 gram per day) usually 
requires treatment with steroids, especially if there is evidence of active urinary sediment, 
elevated anti-double stranded DNA, or low C39. Prednisolone is given in the dose of 0.5 
and 1 mg/kg of or equivalent per day for from four to twelve weeks and subsequently, 
5tapered by 5-10 mg increments every 1-3 weeks9.  
WHO CLASS III and IV-PROLIFERATIVE: Clinicians recommend cyclophosphamide 
contemporaneously with prednisolone for Class III or Class IV disease, especially in the 
presence of moderate to high activity and elevated chronicity biopsy scores. 
Cyclophosphamide is administered at a dose of between 0.5 and 1 gram per m2 of body 
surface monthly for six months. Cyclophosphamide is typically administered with 
between four to 24 hours of intravenous hydration to avoid hemorrhagic cystitis. Those 
centers who use abbreviated intravenous hydration often use two mercaptoethylamine 
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sulfonate sodium (MESNA) to further minimize the risk of bladder toxicity. Ondansetron 
or granesetron can be used as an anti-emetic to reduce nausea and vomiting.  
Use of prednisolone as first line therapy of even Class III and IV disease is the 
observation that remissions of proliferative nephritis have been observed with oral 
steroids, some with no recurrence of nephritis during follow-up periods of 30-40 years23. 
Also, treating with prednisolone alone allows for preservation of reproductive function 
such that pregnancies can be completed in intervals before relapsed disease requires 
cyclophosphamide33. It is also notable that the efficacy of cyclophosphamide is best 
established in patients previously treated for their renal disease with steroids. In the study 
by Austin et al., comparing prednisolone with cyclophosphamide therapy, patient 
enrollment occurred only after a mean of 22 months of treatment with steroids for 
nephritis and 3 years for SLE. The benefits of intravenous cyclophosphamide were 
achieved in groups of patients failing prednisolone, establishing cyclophosphamide as 
salvage or rescue therapy for patients unresponsive to steroids16,33,34. The major argument 
against using steroids alone for proliferative nephritis, especially Class IV, is concern that 
any delay in initiating treatment with cyclophosphamide will permit renal scarring, which 
may be underestimated by serum creatinine and creatinine clearance. Therefore, 
treatment should be individualized accounting for the prognostic information available 
from the clinical or biopsy data and the relative risks of treatment in the specific 
circumstance.  
Once initiated the duration of cyclophosphamide therapy is also individualized. 
For patients with a less prognostically severe biopsy and an early clinical response, 
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cyclophosphamide can be limited to the six month induction course of treatment. 
Boumpas et. al. established that patients with a longer course of cyclophosphamide (i.e. 
14 treatments over 30 months) had a lower incidence of relapse of nephritis, maintenance 
therapy consisting of the same dose of cyclophosphamide administered every three 
months for an additional one to two years is indicated for patients with prognostically 
severe biopsies35. 
Prednisolone and cyclophosphamide therapy of proliferative lupus nephritis is 
usually effective in between 60 and 90% of patients. However, there will be patients who 
will prove refractory, defined as either failing to respond, or relapsing with reappearance 
of a nephrotic syndrome or nephritic component (i.e. hypertension and active urinary 
sediment) sometimes even with loss of renal function that require intensification of 
therapy. These patients may be treated with the resumption of monthly dosing of 
cyclophosphamide, the addition of higher doses of glucocorticoids which can consist of 
either 1 mg/kg per day of prednisone or equivalent, or pulses of methylprednisolone such 
as 1 gram per day for from one to three days. The combination of methylprednisolone 
and cyclophosphamide on a monthly basis in these patients may prove effective, although 
is certainly associated with the range of toxicities attributable to each of these aggressive 
treatments. The addition of plasmapheresis synchronized or otherwise is of uncertain 
benefit in this setting.  
Alternative approaches to patients with proliferative nephritis would include 
initial therapy with prednisone plus azathioprine, prednisone followed by azathioprine, or 
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prednisone plus cyclophosphamide during the six month induction followed by 
maintenance with azathioprine.  
 In a study by Tak Mao et al, eighty-one percent of the 21 patients treated with  
 
mycophenolate mofetil and prednisolone (group 1) had a complete   remission, and 14  
 
percent had a  partial remission, as compared with 76 percent and 14 percent,  
 
respectively, of the 21 patients treated with cyclophosphamide  and prednisolone  
 
followed by azathioprine and prednisolone (group 2). The improvements in the degree of  
 
proteinuria and the serum albumin and creatinine concentrations were similar in the two  
 
groups36. 
 
MMF (2 g/day) was used in combination with steroids in patients with diffuse  
 
proliferative glomerulonephritis43, but not with membranous glomerulonephritis37.  
 
Indications of use included toxicity (60 %) and lack of efficacy (15 %), while in five  
 
patients MMF was used as a first choice agent. Treatment failure was recorded in 20 % of  
 
patients, all with class V nephritis, partial remission in another 20 %, while 60 % went  
 
into complete remission. Proteinuria and creatinine levels were significantly reduced in  
 
patients with proliferative nephritis but not in those with membranous nephritis37. Based  
 
on the above facts, MMF therapy appears to be safe and probably efficacious for the  
 
treatment of lupus nephritis, particularly in proliferative forms in cases of failure or  
 
toxicity of conventional therapy. 
WHO CLASS V-MEMBRANOUS: Class V membranous lupus nephritis is often treated 
with 1 mg/kg per day of prednisone or equivalent for six to twelve weeks. Regardless of a 
response, steroids are usually then discontinued. Cyclophosphamide is generally reserved 
for those patients who have a concurrent proliferative component with their lupus 
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membranous nephritis and continue to have clinical features of activity which typically 
requires not only proteinuria but either an active urinary sediment, persistent high anti-
DNA, or hypocomplementemia. Therefore, patients with lupus membranous nephropathy 
and persistent nephrotic syndrome who have a component of proliferative nephritis are 
considered for cytotoxic therapy. Patients with pure membranous nephritis and incessant 
nephrotic syndrome are candidates for therapy with cyclosporin38. The dose typically is 
3.5 mg to 5 mg/kg per day with close monitoring of the blood pressure and for a 
paradoxical effect on the serum creatinine reflective of the nephrotoxic effects of this 
agent.  
WHO CLASS VI-GLOMERULOSCLEROSIS: This improvement has been attributed to 
a number of different factors including the more judicious use of corticosteroids, 
refinements in immunosuppressive therapy, more effective treatment of hypertension and 
cardiovascular disease, and greater availability of dialysis and renal transplantation39. 
In the routine management of lupus renal disease, the addition of plasmapheresis 
to steroids and cyclophosphamide compared to steroids and cyclophosphamide alone, 
proved of no benefit40. Plasmapheresis is most useful in lupus patients with thrombotic 
microangiopathic hemolytic anemia or secondary TTP. The renal disease that 
accompanies this syndrome is clearly responsive to plasmapheresis with plasma 
exchange. Synchronized plasmapheresis based on the theory of "stimulation depletion" 
was initially reported to be of benefit41. Synergism between pheresis and cytotoxic 
treatment was predicted on the concept that plasmapheresis is followed by a period of 
accelerated B cell proliferation such that synchronized doses of cyclophosphamide would 
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have the greatest cytolytic effect on autoreactive anti-DNA producing clones of 
lymphocytes. However, a more recent study suggested that synchronization was of no 
greater benefit than standard cyclophosphamide and low dose prednisolone treatment yet 
associated with greater toxicity42,43 . 
Intravenous immunoglobulin is a relatively less toxic, although expensive 
approach to the treatment of lupus and lupus renal disease. However, save for scattered 
case reports, there is no convincing data to state with any certainty its benefits. 
Intravenous immunoglobulins can be associated, albeit rarely, with acute renal failure; 
presumably on the basis of tubular injury related to the infused immunoglobulin. 
General Measures 
In a study by J. Font et al on the cardiovascular risk factors and the long term  
 
outcome in lupus nephritis, compared with controls, LN patients had a higher prevalence  
 
of hyperlipidaemia  (44% vs. 2%, p=<0.001), hypertension (44% vs. 9%, p=<0.001) and   
 
antiphospholipid antibodies (44% vs. 22%, p=0.01) at study onset.  Hyperlipidaemia  
 
(78% vs. 27%, p<0.001) and hypertension (67% vs. 32%,p=0.01) at study onset were  
 
associated with renal failure44. 
Despite the best of efforts some patients will develop ESRD. Seasoned clinicians, 
familiar with the generally good experience with hemo and peritoneal dialysis as well as 
renal transplantation in lupus patients45, recognize the need to abandon 
immunosuppressive therapy once advanced glomerulosclerosis has developed.  
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Novel Therapies 
Specific agents that are undergoing clinical investigation include LJP397, which 
is known as a B cell tolerogen. It consist of four oligonucleotides attached to a triethylene 
glycol platform, which when infused, is bound by the Fab portion of anti-DNA antibodies 
in the membrane of auto-reactive B cells. Cross linking of anti-DNA antibody in the cell 
membrane of B cells results in a down regulation of anti-DNA immunoglobulin synthesis 
and apoptosis of these B cells. In animal models of lupus renal disease, this approach has 
not only reduced the production of anti-DNA, but mitigated renal disease. Human studies 
have suggested that this is a non-toxic therapy and beginning in 1997 a multicenter 
randomized double blind study investigating its efficacy was initiated46. 
Additional agents that may have a role in the treatment of lupus nephritis include 
a monoclonal antibody to the fifth component of complement. The monoclonal anti-C5 
reduces the production of C5a and C5b-9 and the inflammatory reaction which appears 
consequent to the generation of immune complexes in the kidney. 
 An additional agent, anti-CD40ligand monoclonal antibody, has the ability to 
reduce the production of auto-antibodies. Anti-CD40ligand not only inhibits production 
of pathogenic antibodies but can inhibit inflammatory cytokine production and T cell 
dependent activation of endothelial cells46.   
 
 
Predictors of Outcome In Lupus Nephritis 
 
Because of the high heterogeneity of SLE among patients and the limited  
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therapeutic resources available at present that may induce substantial toxic effects in the  
 
long term47, it is important to identify those patients who may have a worse prognosis,  
 
and thus necessitate more-aggressive treatments to prevent or reduce complications and  
 
organ failures. 
 
The predictors of outcome and long-term prognosis in patients with lupus  
 
nephritis are48,49,   
 
1. Disease severity, both in terms of clinical manifestations (serum                         
 
creatinine and proteinuria) and histopathology; 
 
2. Patients' characteristics: age and sex, race and ethnicity,  
 
socioeconomic status and access to healthcare; 
 
3. Response to therapy; and 
 
4. Specific treatment modalities. 
 
Old data published by Estes and Christian50 in the 1970s pointed to an estimated  
 
5-year survival rate for patients with renal manifestations of about 50% vs. 75% for the  
 
whole SLE series analyzed. Such a rate was even lower for patients with severe kidney  
 
disease: about 68% for patients with focal proliferation, but only 28% for those with  
 
diffuse and membranous lesions. Patients in this series were being treated with 40 mg of  
 
prednisolone, the conventional treatment at the time, as immunosuppressive agents were  
 
not yet in use 50. 
 
In a 1965-1998 series of 800 patients followed at SUNY/Brooklyn, the average  
 
survival rate of SLE patients with kidney disease was, overall, 60% to 65% at 300-350  
 
months51. 
 
Of note, the effect of the inclusion of socioeconomically disadvantaged patients  
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had a far less negative effect than reported in other series. It showed a trend, but it did not  
 
reach a significant difference. It is unclear whether the socioeconomic factors did not  
 
play such a significant role in this cohort or whether better care than average was  
 
provided to these patients. 
 
Notwithstanding these successes, and the fact that SLE-related mortality has been  
 
significantly reduced with medical intervention in the past 20 years or so, there has been  
 
a 3-fold increase in morbidity, thus leading to an increase in the overall burden of  
 
disease. 
 
A number of other factors have been shown to be of critical importance in  
 
predicting worse outcome for patients with severe LN in a study of 65 patients32: 
 
1. Initially high serum creatinine; 
 
2. Lower hemoglobin/hematocrit; 
 
3. Black race; and 
 
4. The presence of interstitial fibrosis and crescents (which are a sign of  
 
chronicity and damage). 
 
 
Effects of Treatment On Outcome Of Lupus Nephritis 
 
Achievement of remission following treatment, as well as the type of treatment  
 
given, seem to have a considerable effect on outcome52,  as reported by Korbet and  
 
colleagues53. Patients receiving conventional treatment had a survival rate of 95% at 5  
 
and 10 years that was reduced to 69% at 5 years and 60% at 10 years in those patients  
 
who did not achieve remission. Treatment with high-dose prednisolone plus  
 
cyclophosphamide plus/minus plasmapheresis substantially improved the survival rate  
 
also in renal patients achieving remission - 94% at 5 and 10 years. Lack of remission was,  
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however, associated with a far lower survival rate, 45% and 31% at 5 and 10 years,  
 
respectively, in patients with refractory renal disease. 
 
Clinical remission in the overall series was achieved in 43% of patients (37/86).  
 
Overall time to remission was 16 months (± 14 months) and the median, 10.5 months.  
 
The positive predictors of remission included a stable renal function, a lower chronicity  
 
index, and white race. Also, the probability of developing end-stage renal disease seemed  
 
strongly correlated with choice of treatment. Intravenous or oral cyclophosphamide  
 
plus/minus azathioprine was associated with the lowest risk of renal failure (5% to  
 
25%), risk that increased to 40% with azathioprine alone and up to 80% with  
 
prednisone only53. 
 
A recent European study by Houssian and colleagues54 has reported similar  
 
outcome in patients receiving high- vs low-dose cyclophosphamide, being the latter a  
 
regimen that is becoming the new standard of care in Europe, to avoid the toxic effects  
 
and cancer risk(s) associated with long-term, high-dose immunosuppressive therapies.  
 
Long term data on the prognosis of these patients are yet to come. 
 
 
Influence of Socioeconomic and Genetic Factors on Outcome Of Lupus Nephritis 
 
The influence of race on outcomes of SLE patients shows a different penetrance  
 
in different studies, and the underlying mechanisms are still poorly understood.  
 
Nonetheless, the survival rates of renal patients evaluated 5 years after renal biopsy were  
 
significantly different in 2 cohorts (P = .007), with > 90% survival in white vs 60% in  
 
black SLE patients55. When the effect of race on survival was evaluated with other  
 
parameters, it was found to be independent of age, the duration of SLE, hypertension, and  
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cyclophosphamide treatment. In the SUNY/Brooklyn series mentioned before, there was  
 
a trend in favor of white and Asian patients, but such a difference did not reach  
 
significant values51. 
 
In a series of 128 patients evaluated at Columbia University, New York, NY,  
 
patients with evidence of poverty had a 3.5% higher relative risk of progression (a shorter  
 
time to doubling of serum creatinine) after adjustment for age, hypertension, and  
 
cyclophosphamide treatment. In another study performed in New York City, mentioned  
 
by Dr. Ginzler48, the impact of poverty appeared significant with a survival rate at 65  
 
months of 42% in renal patients with evidence of poverty vs. 78% in above-poverty- 
 
level patients. It is unclear whether access to healthcare, education, and quality of  
 
nutrition are all factors contributing to such differences. It cannot be excluded that  
 
different factors may be differentially implicated in the various cohorts studied. Recent  
 
investigations of the molecular and genetic mechanisms involved in SLE seem to suggest  
 
a genetic predisposition to SLE in black patients56. The increased prevalence of the  
 
Fcgamma receptor 2A28, increased titers of immunoglobulin (Ig)G2 specific for C1q57,  
 
and decreased clearance of circulating immune complexes (CICs) reported in these  
 
patients may all potentially contribute to a reduce clearance of CICs and, thus, to a higher  
 
risk of renal disease. 
 
More insight in the etiopathogenic factors of SLE is expected from the ongoing  
 
studies on the basis of gene expression microarrays, genomic analysis, and the refined  
 
classification of renal disease in SLE patients. At the same time, glomeruli isolated by  
 
laser capture microdissection will allow more detailed analyses of the damage inflicted to  
 
the kidney by SLE and correlations with response to medical therapy. 
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Role of Antiphospholipid syndrome in Lupus Nephritis 
 
 APS is characterized by recurrent arterial or venous thrombotic events and/or 
pregnancy morbidity along with the sustained presence of antiphospholipid antibodies 
(anticardiolipin antibodies and/or lupus anticoagulant)58. Renal disease in 
antiphospholipid syndrome is characterized by interstitial tubular or glomerural injury 
due to obstruction of large, medium, or small-sized vessels59. In a recent study, 
Vlachoyiannopoulos et al studied renal involvement in a cohort of 248 patients with SLE 
and APS syndrome with positive titre of anticardiolpin antibodies, among which 40 % 
had evidence of renal involvement60. A renal biopsy was performed in 79 % of patients 
for diagnostic purposes. Patients with APS experienced high percentages of hypertension 
(59 %) compared to those without the syndrome, while increased levels of creatinine, 
proteinuria, and hematuria with or without the presence of casts were similar in both 
groups. Renal biopsy analysis revealed that the main histopathologic finding in APS 
patients compared to controls was hyperplasia of intima (64 % vs. 19 %, p<0.001). 
Thrombi and atrophy of renal tubules were common but not pathognomic, since they 
were found in both groups. Renal biopsy findings determined further therapeutic 
approach to these patients. When findings are consistent with lupus nephritis, according 
to World Health Organization (WHO) classification, standard care with intravenous 
cyclophosphamide pulses and corticosteroids is recommended61. When thrombi and 
intimal hyperplasia predominate, the patient should be placed on long-term oral 
anticoagulant therapy. 
Lupus Nephritis: Prognosis 
 
 With modern treatment, the survival has improved in the west to about  
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of 80% at 10 years after diagnosis12 but, the Indian figures are not so good and is about  
 
50%-60% survival at 10 years13,14. Possible reasons for poor survival in Indian SLE  
 
include delay in diagnosis, referral bias (only the most serious cases are referred by  
 
practitioners), suboptimal health care facilities and an inherently more severe disease  
 
(genetic factors?) and endemic tuberculosis to which the lupus patients are more  
 
susceptible. 
 
As shown by Fiehn et al, in the decade from 1990 to 2000 there was significantly  
 
less proteinuria (46 v 17g/l, p=0.008), significantly lower rates of renal failure (40% v  
 
17%, p=0.02), and fewer histological signs of chronicity (33% v 10%, p=0.01) at the time  
 
of diagnosis of LN than in the decade from 1980 to 198962. The mean (SD) time from the  
 
first appearance of proteinuria until kidney biopsy was significantly shorter in the later  
 
decade [15.4 (15.6) vs. 3.9 (4.7) months]. Though treatment schedules were not  
 
significantly different, the outcome of the disease was  significantly better in the patients  
 
who were diagnosed with LN between 1990 and 2000 (p=0.045)62. 
 
A number of factors have prognostic significance from a clinical point of view, as  
 
including persistent anemia, severity of the disease64,65, time to treatment, and duration of  
 
remission. In patients treated with intravenous cyclophosphamide, an age at diagnosis of  
 
< 29 years was found associated with a higher risk of progression to LN in 5 years. Also,  
 
an advanced chronicity  index (> 3) at biopsy and a delay to treatment of > 5 months  
 
were linked to worse outcomes66.  
 
Patients who did not have a flare-up of their disease had only a 25% risk of  
 
doubling their serum creatinine in 5 years vs. a 75% risk in patients who experienced  
 
flare- ups in the observation period. Austin and colleagues32 reported in 1994 that the  
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presence of focal necrosis, crescents, proteinuria, lower C3 (< 76 mg/dL) following  
 
therapy, female sex, age > 30 years, black race, and hematocrit of < 26% were associated  
 
with a worse outlook. The difference reported by the 2 groups in age significance has not  
 
been clarified. Treatment can critically improve the survival of SLE patients with renal  
 
disease. In a study by Laitman and colleagues67, patients in group 1a (with  
 
relapsing/recurrent grades 2, 3, and 4 LN) had a survival of about 80% at 6 years vs. less  
 
than 5% for patients in group 1b who also had grades 2, 3, and 4 LN, but were refractory  
 
to medical treatment. Patients in group 2 (with grades 3 and 4 LN) with recurrent disease  
 
had an intermediate survival rate. 
 
If patients were treated within 5 months of diagnosis, they had a 25% chance of  
 
relapse of their renal disease at 7-10 years. Conversely, if they were treated only after 5  
 
months from biopsy, their chances of relapse increased to 60%66. 
 
Use of renal biopsies is critical in the management of lupus patients in diagnostic,  
 
therapeutic, and prognostic terms32. The presence of cellular crescents and interstitial  
 
fibrosis was found associated, in addition to endocapillary proliferation, with an  
 
increased risk of progression (doubling of serum creatinine) in 40-50 months from 20%  
 
to 80% of cases. A global disease activity of < 1.73 was associated with progression  
 
(doubling of serum creatinine) at 4000 days in only 15% of cases vs. 80% in patients with  
 
a disease activity of > 1.7368. Persistent inflammation and positive findings at  
 
immunofluorescence are also predictive. Progression was seen in 75% of patients with  
 
karyorrhexis vs. 26% in patients who were negative. Similarly, progression was seen in  
 
69% of patients with crescents vs. 33% of control patients. Reinduction therapy with  
 
pulse steroids and intravenous cyclophosphamide in 12 refractory LN patients, however,  
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achieved a reduction of progression risk from 34% to 10.5% in patients with crescents,  
 
and from 73% to 6.4% in patients with biopsies positive for endocapillary proliferation.  
 
Follow-up biopsies at 6 months were negative for cellular crescents, endocapillary  
 
proliferation, and karyorrhexis. Reinduction therapy was effective in salvaging LN  
 
patients who were otherwise refractory to treatment63. 
 
  In summary, we find paucity of data regarding short term outcome and its  
 
predictors in Indian patients with lupus nephritis. This may go a long way in view of  
 
changing scenario of outcome due to early diagnosis and newer drugs. Although majority  
 
of the lupus nephritis patients belong to class IV and there is an Indian study on this  
 
class of patients69, the overall picture has not been brought out by any Indian study on  
 
lupus nephritis. It is with this background that we have endeavored this study.  
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AIM 
 
  
 
T o describe the presentation of lupus nephritis, its prognostic factors,   
 
outcome measures and their correlation  in patients with lupus nephritis on  treatment  
 
for six months.  
 
 
 
 
 
 
 
OBJECTIVES 
 
 
1. To describe the presentation of lupus nephritis in our population     
 
2. To describe the clinical outcome of lupus nephritis in patients treated with various  
 
regimens at six months.  
 
3. To identify predictors of outcome of lupus nephritis in our population. 
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MATERIALS AND METHODS 
Setting   Study was conducted among the patients presenting to the  
in-patient and out-patient services of the Department of Medicine  
and Nephrology of the Christian Medical College (CMC), Vellore,  
South India which is an 1800 bedded tertiary care teaching  
hospital.    
 
Duration Of Study  
 
August 2004 to July 2006. The recruitment of patients  
 
ended in January 2006 and the follow up period in July 2006. 
 
Inclusion Criteria  
 
1. All consecutive adult SLE patients (age >12 years).  
 
2. Diagnosed with lupus nephritis by Renal biopsy in the  
 
Department of Medicine and Nephrology.  
 
3. Follow up for 6 months, availing out-patient clinic/ in-patient  
 
services between August 2004 and July 2006.  
 
Exclusion Criteria  
 
1. Age < 12 years. 
  
2. Renal disease other than SLE. 
 
3. Less than 6 months of follow up. 
 
Study Design   
 
The study was a Prospective Cohort study on consecutive  
 
Lupus Nephritis patients diagnosed in our centre.  
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Study Protocol 
 
   
 All consecutive adult patients diagnosed to have SLE and admitted for renal  
 
biopsy were enrolled into the study. Upon enrolment into the study, complete  
 
demographic details, relevant clinical and laboratory parameters were collected. The SLE  
 
disease severity was assessed using the SLEDAI score (SLE Disease Activity  
 
Index) which is a validated index for assessing disease activity29,30,35 (Annexure A).   
 
The following specific data was collected at the time of enrolment  
 
into study through a Proforma (Annexure B): 
 
1. Demography- Age, Sex, Region, Marital status 
 
2. Clinical presentation of SLE 
 
3. Clinical presentation of Lupus Nephritis 
 
4. SLEDAI  score 
 
5. Biopsy findings of lupus nephritis 
 
6. Laboratory parameters at enrolment 
 
7. Treatment regimens planned 
 
8. Co-morbidities 
 
 
The participants underwent treatment as per the policies of the various  
 
Departments namely steroids and Cyclophosphamide pulse, steroid and Azathioprine,  
 
steroid and MMF, steroid alone, IVIG and others. 
 
 
The patients who came for follow up at the end of six months were  
 
finally enrolled for the analysis. The following specific data was collected at  
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the end of six months through the same Proforma (Annexure B). 
 
1. SLEDAI score and other clinical parameters 
 
2. Laboratory parameters at six months 
 
3. Outcome Variables- Complete remission, Partial remission, No Remission,  
 
Relapse70 which are defined below. 
 
A. Complete Remission- Defined as <10 dysmorphic erythrocytes per  
 
high power field, the absence of cellular casts, and excretion of <1G of  
 
protein per day without doubling of  s.creatinine level. 
 
B. Partial Remission- Defined as the reduction of at least 50% in  
 
- the number of dysmorphic erythrocytes seen in urine sample  
 
- the number of cellular casts  
 
- proteinuria 
 
- without a doubling of the s.creatinine level 
 
 C. No Remission- >/= 10 erythrocytes per high power field, cellular  
 
casts, proteinuria ( >1G of protein per day), and doubling of s.creatinine  
 
level. 
 
D. Renal Relapse- Increase in at least 50% in any two of the following  
 
after six or more months of remission: number of dysmorphic RBCs >/=10  
 
per high power field, number of cellular casts, proteinuria >/= 1G per day,  
 
or s.creatnine level. 
 
   For analysis of data at the end of six months groups “A” and “B”  
 
were taken as RESPONDERS and groups “C” and “D” were taken as  
 
NON-RESPONDERS. 
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4. Various Drug Regimens patients received 
 
5. Drug Toxicities 
 
6.   Infections and other complications 
 
Statistical Analysis 
 
All consecutive patients diagnosed with SLE and who met the inclusion  
 
criteria were enrolled into the study between August 2004 and January 2006. Patients  
 
zero time corresponded to the time of hospital admission for Renal biopsy after which  
 
they were followed up for a total of six months.  
 
Values were expressed in mean +/- SD for continuous variables and No. (%) for  
 
categorical ones. Comparisons between responders and non-responders for continuous  
 
variables were done using Independent t Test and Mann Whitney score for normal and  
 
non-normal (distribution) data respectively. 
  
Paired t Test (normal) and Wilcoxon Signed Rank Test (non normal) were  
 
performed to assess the significant improvement over time. Pearson Chi Square test were  
 
used for categorical variables. Univariate Analysis was carried out to find  
 
significant risk factors associated with poor outcome. 
  
Multivariate analysis were carried out on the various demographic, clinical, lab  
 
parameters factors whose univariate analysis had a p value of <0.025. Multivariate  
 
analysis was done by Enter Method followed by Forward Step Conditional to find out the  
 
significant variable. Values of p <0.05 were considered significant in the multivariate  
 
model..  SPSS version 11.5 was used for the statistical analysis. 
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Consort Diagram 
 
 
 
 
83 CONSECUTIVE PATIENTS ENROLLED 
 
 
 
CR= Complete remission 
PR=  Partial Remission 
NR= No Remission 
R=    Relapse 
D=    Death 
 
 
 
 
 
  
78 patients had a follow up of 6  
months 
 
5 patients were lost to follow up 
CR
=43 
PR
=12 
NR 
=19 
R 
=3
D 
=1
RESPONDERS 
N=55 
NON RESPONDERS 
N=23 
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RESULTS 
  
83 consecutive patients were enrolled into the study and 5 were lost to follow up.  
 
78 patients were analyzed at the end of 6 months of follow up. The Responders were  
 
70.5% and Non responders were 29.5%. 
 
1. Majority of patients were between 21 to 40 years of age, in the reproductive age  
 
group.     
 
Table 1 (Figure 3): Age Distribution vs. Outcome 
 
 
 
p = 0.367 between responders and non responders for all age group 
 
2.  Female to male ratio is 8.7:1.2. 
 
Table 2 (Figure 4): Sex Distribution vs. Outcome 
 
 
Sex Responders 
(N=55) (%) 
Non responders 
(N=23) (%) 
Cumulative 
(N=78) (%) 
Female 47 (85.5%) 21 (91.3%) 68 (87.2%) 
Male 8 (14.5%) 2 (8.7%) 10 (12.8%) 
 
p = 0.481 between responders and non responders between males and females. 
 
 
 
 
Age (years) Responders 
(N=55)  (%) 
Non responders 
(N=23) (%) 
Cumulative 
(N=78) (%) 
0-20 14 (25.5%) 6 (26.1%) 20 (25.6%) 
21-40 32 (58.2%)  12 (52.2%) 44 (56.4%) 
41-60 9 (16.4%) 5 (21.7%) 14 (17.9%) 
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3. The extra renal organ manifestations of Lupus Nephritis were compared between the  
 
outcome groups to look for significant predictors of poor outcome. The prevalence of  
 
various extra renal manifestations  in lupus nephritis patients were 64.5% for  
 
mucocutaneous, 60.5% for arthritis, 9.2% for serositis, 5.3% for CNS involvement and  
 
40.8% for hematological involvement. The responders seemed to have a higher  
 
incidence of muco-cutaneous and arthrtic manifestations. There was no significant  
 
correlation of any extra renal organ involvement with poor outcome. 
 
 
 
Table 3 (Figure 5): SLE clinical manifestations* vs. Outcome 
 
 
 
 
Clinical 
Parameters 
 
Responders 
 
(N=53) (%) 
Non 
Responders 
(N=23) (%) 
Cumulative 
 
(N=76) (%) 
p value 
Mucocutaneous 40 (75.5%) 9 (39.1%) 49 (64.5%) 0.002 
Arthritis 38 (71.7%) 8 (34.3%) 46 (60.5%) 0.002 
Serositis 5 (9.4%) 2 (8.7%) 7 (9.2%) 0.919 
CNS involvement 3 (5.8%) 1 (4.3%) 4 (5.3%) 0.801 
Hematological 23 (43.4%) 8 (34.8%) 31 (40.8%) 0.482 
 
* Overlapping features in a patient will cause the total of each column to be  
 
more than the actual number of patients 
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4. The mean time of biopsy for our patients was 7.98 +/- 1.9 months. There was no  
 
significant correlation between responders and non responders (p= 0.191). Among all  
 
patients 47% had renal biopsy at diagnosis of SLE,  82% by 1 year and  89.7% by 2  
 
years. 
 
 
 
5. We compared the various laboratory parameters of lupus nephritis between the two  
 
outcome groups. It was found that Creatinine clearance <75ml/min, and Proteinuria  
 
were significant predictors of poor outcome. But S.creatinine >1.5 mg/dl,  
 
RBCs >10/hpf and elevated dsDNA did not have any correlation with the outcome.   
 
 
 
Table 4 (Figure 6): Laboratory Parameters vs. Outcome 
 
 
 
Lab Parameters 
 Responders
(N=55) 
Non 
responders 
(N=23) 
Cumulative 
(N=78) 
p 
value 
Active sediments 
(RBCs >10/hpf) 
24 (43.6%) 13 (56.5%) 37 (47.4%) 0.299 
Proteinuria (>3.5 G) 37 (67.2%) 12 (52.1%) 49 (62.8%) 0.208 
S.Creatinine (≥1.5 
mg/dl) 
7 (12.7%) 6 (26.1%) 13 (16.7%) 0.149 
Elevated DsDNA  47 (85.5%) 19 (82.6%) 66 (84.6%) 0.639 
Creatinine Clearance 
(<75ml/min) 
20 (36.4%) 14 (60.9%) 34 (43.6%) 0.047 
  
However, Proteinuria as a continuous variable using the Mann Whitney test  
 
of Significance was found to be significant predictor of non responsiveness to  
 
therapy with a p value = 0.032. 
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6. Among the other lab parameters analyzed,  S.albumin showed significant correlation  
 
with outcome.  
 
 
 
Table 5 (Figure 6): Laboratory Parameters vs. Outcome 
 
 
 
Lab Parameters 
 
Responders 
(N=55) 
Non 
responders 
(N=23) 
Cumulative 
(N=78) 
p 
value 
Platelets (<1 lac /cu.mm) 7 (17.4%) 4 (12.7%) 11 (14.1%) 0.589 
Hemoglobin (<10 mg/dl) 27 (49.1%) 13 (56.5%) 40 (51.2%) 0.561 
 
 
 
S. Albumin was done in 69 out of 78 patients at the time of diagnosis and a  
 
value of </=3.0 mg/dl was found to be significant predictor for non responsiveness to  
 
therapy (p value of 0.041). 
 
 
 
S. Complements (C3/C4) was done on 67 out of 78 patients at the time of  
 
diagnosis and low complements was not found to be a significant predictor for non  
 
responsiveness to therapy (p value of 0.143). 
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7. The SLEDAI score and the various lab parameters were statistically analyzed for any  
 
significant change in their values with treatment over six month period in both the  
 
outcome groups namely Responders(R) and Non responders (NR).  
 
Table 6a (Figure 7-9): Change in Parameters over Time 
 
 
Table 6b (Figure 10-12): Change in Parameters over Time 
 
 
*The colours of p value depicted corresponds to the colours in the figure. 
 
 Values were also compared between Responders and Non responders at 6 months,  
 
and the following parameters were significantly different namely, SLEDAI score  
 
(p value= 0.000), S.Albumin (p value= 0.00),  S.Creatinine (p value= 0.00) and  
 
Proteinuria (p= 0.00). 
Time Hemoglobin 
Mean(mg/dl) 
(SD) 
Platelets mean 
(Lac/cu.mm) 
(SD) 
Proteinuria 
Mean(G/dl) 
(SD) 
S.Albumin 
(mg/dl) 
(SD) 
 R NR R NR R NR R NR 
0 months 10.0 
(1.9) 
9.2 
(2.4) 
1.97 
(1.01) 
1.86 
(0.57) 
2.8 
(3.2) 
3.79 
(2.26)
2.6 
(0.93) 
2.2 
(0.73) 
6 months 11.6 
(1.8) 
9.8 
(2.46) 
2.10 
(1.00) 
1.98 
(0.73) 
0.61 
(0.93) 
3.06 
(2.36)
3.7 
(0.62) 
2.7 
(1.06) 
p value* 0.000 0.372 0.244 0.307 0.000 0.181 0.000 0.155 
Time Complement 
Mean(mg/dl) 
(SD) 
DsDNA  
Mean (Au/ml) 
(SD) 
S. creatinine 
Mean (mg/dl) 
(SD) 
SLEDAI 
Score 
(SD) 
 R NR R NR R NR R NR 
0 months 58.2 
(19.4) 
58.2 
(19.4) 
51.9 
(33.7) 
42.5 
(13.8) 
1.02 
(0.56) 
1.34 
(0.71) 
17.9 
(6.37) 
17.95 
(6.7) 
6 months 73.7 
(15.7) 
73.7 
(15.7) 
25.7 
(12.6) 
25.07 
(9.49) 
0.88 
(0.59) 
1.5 
(1.11) 
5.6 
(4.5) 
12.0 
(5.9) 
p value* 0.000 0.055 0.000 0.004 0.003 0.552 0.000 0.007 
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The following graphs from 7-12 show change in  different clinical  
 
and lab parameters over six months among Responders and Non  
 
Responders and their correlation 
 
 
 
Figure7 
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Figure 8 
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Figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Au is the arbitrary unit of the commercial kit 
 
Figure11 
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Figure 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in Proteinuria in Outcome Groups
0
2
4
0 Months 6 Months
Time From  Biopsy
Pr
ot
ei
nu
ria
 (G
/d
l)
Responders
Non Responders
p= 0.000 
p= 0.181 
p= 0.000 
mean 
 46
 
 
 
8. Two third (66.7%) of patients had WHO class IV lupus nephritis. The distribution of  
 
other classes among the outcome groups have been shown in the table below.  
 
 
Table 7 (Figures 13a and 13b): WHO Class Histology distribution in 
the Outcome Groups 
 
 
WHO Class Responders 
(N=55) 
Non responders 
(N=23) 
Cumulative 
(N=78) 
I 1 (1.8%) 0 1 (1.3%) 
II 15 (27.3%) 2 (8.7%) 17 (21.8%) 
III 3 (5.5%) 0 3 (3.8%) 
IV 33 (60%) 19 (82.6%) 52 (66.7%) 
V 3 (5.5%0 1 (4.3%) 4 (5.1%) 
VI 0 1(4.3%) 1(1.3%) 
  
 
 
When WHO Class IV was compared with the rest of the classes as a  
 
predictor of non responsiveness to therapy, it was significant with a p value= 0.053. 
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Figure 13a 
                        WHO Class In Responders 
Figure 13b 
                   WHO Class In Non Responders 
 
Responders
I
II
III
IV
V
VI
1
15
3 
33 
3 
 
N= 55 
Class VI = 0 
Non responders
I
II
III
IV
V
VI
2
19 
1 
1 
N= 23 
Class I and III = 0 
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9. The various co-morbidities studied included hypertension, diabetes, hypothyroidism  
 
and associated antiphospholipid syndrome (APLAS).It was found that hypertension  
 
was a significant predictor of poor outcome with a p value = 0.002. 
 
 
 
 
Table 8 (Figure 14): Correlation between Co Morbidities vs. Outcome 
 
 
Co morbidities Responders 
(N=55) 
Non responders 
(N=23) 
Cumulative 
(N=78) 
P 
value 
Hypertension 10 (18.2%) 12 (52.2%) 22 (28.2%) 0.002 
APLA syndrome 12 (21.8%) 3 (13%) 15 (19.2%) 2.223 
Diabetes 3 (5.5%) 2 (8.7%) 5 (6.4%) 0.594 
Hypothyroidism 14 (25.5%) 2 (8.7%) 16 (20.5%) 0.095 
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Figure 14 
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Table 9: Multivariate analysis for the variables significant in the Univariate  
 
analysis using the ENTER method of Logistic Regression. 
 
 
Variables p value Exp (B) 95% CI for Exp(B) 
   Lower Upper 
WHO Class IV 0.295 2.270 0.489 10.52 
Creat Cl. (<75ml/min) 0.543 1.563 0.371 6.58 
S. Albumin (<3.0mg/dl) 0.184 2.965 0.59 14.7 
Hypertension 0.065 3.568 0.92 13.7 
Proteinuria 0.797 1.0 1.0 1.0 
SLEDAI 0.574 0.973 0.88 1 
 
 When the Logistic regression was done using the Forward Stepwise  
 
Conditional Method, Hypertension was found to be significant predictor of Non  
 
responsiveness to therapy with a p value = 0.007 (C.I.95%=1.556-15.672). 
 
 
10.  Though the treatment regimens were at the discretion of the physicians and  
 
nephrologists, most of them followed standard established literature. Only one patient  
 
had Class I lupus nephritis and was treated with low dose steroids over 6 weeks and  
 
responded to therapy. 
 
 Out of the 17 patients in Class II, 12 of them received prednisolone with  
 
azathioprine (1 non responders), 4 received prednisolone alone (2 non responders) and  
 
one received prednisolone with oral cyclophosphamide. 
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All 3 patients in Class III and 46 out of 52 patients in Class IV lupus nephritis,  
 
received steroids with monthly Cyclophosphamide pulse (0.5-1g/m2) for 6 months  
 
followed by three monthly pulse. There were no non responders in Class III and 17 non  
 
responders in Class IV. One patient in Class IV developed leucopenia and hence  
 
Azathioprine was substituted at two months, as patient could not afford MMF. Total of 3  
 
patients in Class IV received Azathioprine and steroids (2 non responders). Two of these  
 
patients did not accept the toxicities of Cyclophophamide and at the same time could not  
 
afford MMF for their treatment. One of them was given Azathioprine for  
 
cyclophosphamide induced leucopenia and because of the affordability factor. A total of  
 
3 patients in Class IV received MMF.  
 
 Out of the 4 patients in Class V, two received Azathioprine with steroids (1 non  
 
responder), one received only steroids and one received Cyclosporine. There was only  
 
one patient in Class VI who was conservatively managed and was a non responder. 
 
 No statistical analysis could be done between the three treatment arms because of  
 
very few patients in the Azathioprine and MMF groups. 
 
11. Seventeen patients had only one episode of infection, 5 patients had 2 episodes of  
 
infection and 2 patients had 3 episodes of infection. One patient had Sepsis and died at  
 
five months of follow up. There were no ICU admissions. 
 
 
 
 
 
 
 
 
 
 52
 
 
Table 10: Infection Sites and Rates in Responders and Non  
 
Responders. 
 
 
 Responders (N=55) Non Responders (N=23) 
Infection 16 (29%) 8 (34.7%) 
No. of episodes 22 (40%) 11 (47.8%) 
Type  of infection     
Respiratory Infection 7 (12.7%) 4 (17.3%) 
Urinary tract Infection 4 (7.2%) 1 (4.3%) 
Tuberculosis 1 (1.8%)  
Muco-cutaneous 7 (12.7%) 4 (17.3%) 
Others 3 (5.4%) 2 (8.6%) 
 
 
  
Table 11: Complications associated with Steroid during the six months  
 
Treatment Period. 
 
 
Complication No. of  Patients 
Steroid induced Cushings 4 
Steroid induced Diabetes 5 
Probable Steroid induced Hypertension 3 
Osteoporosis 3 
Avascular Necrosis 2 
Cataract 3 
Gastrointestinal  1 
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Out 46 patients on Cyclophosphamide for WHO class IV lupus nephritis, 1 had  
 
leucopenia. This patient had Azathioprine instead. No patient among the 78 had   
 
hemorrhagic cystitis or amenorrhea within the 6 months. Out of a total of 22 patients  
 
receiving Azathioprine in the various WHO classes, only one had  pancytopenia  which  
 
recovered and the drug was continued after a period of drug holiday. Only three patients  
 
in class IV lupus received Mycophenolate Mofetil and none of them developed any  
 
complications.  
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Discussion 
 
 
 83 consecutive patients who were diagnosed to have SLE and admitted for renal  
 
biopsy were recruited into the study. These patients were admitted either in Medicine or  
 
in Nephrology  wards for biopsy. Follow up was through outpatient visits to either  
 
department. Data was collected through Proforma (Annexure B). Of the 83, 5 were lost  
 
to follow up. All the 5 were from the North Eastern region of the country. Attempts to  
 
contact them through post was unsuccessful. The analysis was undertaken in the      
 
remaining 78 who had six months of follow up. It compares well with the studies done on  
 
outcome in lupus nephritis. Study done in our centre by Abraham et al and published in  
 
’99 was done on 29 patients with class IV lupus with a follow up of 5 years 69. Other  
 
studies from the West36,70,71,72,73 had sample size ranging from 34-82. 
   
 
 The mean age in our study was 29.5 years with a range of 13-55 years. The  
 
various studies from India have reported the mean age as 24 years (range 4-55 years)4,  
 
and 25.05 years (range 7-48 years)5. This is the reproductive age group in the  
 
vast majority of our population. The mean age in our study was in keeping with that in  
 
the literature. 
 
 The female to male ratio in our study was approximately 9:1 which is the standard  
 
ratio in any literature. Malaviya et al in 1997 reported F: M ratio of 11:1 by among 1366  
 
SLE patients from different regions of the country8. In the West the female: male ratio  
 
rises from 2:1 in prepubertal children up to 4.5:1 in adolescence to the 8 to 12:1 reported  
 
in series of adult onset patients, falling back to 2:1 in patients over 60 yr of age15. 
 
 In our cohort of patients with lupus nephritis, 64.5% patients had associated  
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mucocutaneous manifestations and 60.5% had associated arthritis. It is similar to the  
 
findings in the study by Tak et al done among 42 patients with lupus nephritis, where  
 
mucocutaneous manifestations were 62% and 43%, arthritis was 71% and 57%  
 
respectively, in the two lupus nephritis treatment arms36.   
 
In the study done by Fiehn et al, published in 2003, the mean time of biopsy from  
 
the diagnosis of SLE was 39.3 months in the decade 1990-2000. But the mean time of  
 
biopsy was 7.98 +/- 1.9 months for our patients. This could be because of our tertiary  
 
care set up and the referral bias associated with it. All patients who had renal  
 
biopsy done had evidence of lupus nephritis histologically. This could explain 70%  
 
response to therapy we had at the end of 6 months as against other Asian studies showing  
 
a poorer outcome74, as there was less delay in doing a biopsy and instituting  
 
immunosuppressive therapy in our cohort. Recent modifications to the classification of  
 
lupus nephritis, the emergence of newer scoring indices, and the availability of a variety  
 
of therapeutic options predicate a reassessment of the role of the renal biopsy in the  
 
management of lupus nephritis, especially for patients with proliferative lupus nephritis75.  
 
These patients have a poor outcome if not treated optimally and urine analysis by itself  
 
fails to accurately predict the histological type32. 
   
 
 In our study, s.albumin of <3.0mg/dl was found to be significantly associated with  
 
poor outcome ( p value = 0.041) in the Univariate analysis. Hypoalbuminaemia reflects  
 
significant protein loss in urine and the underlying malnourished state and hence  
 
decreases the chance for a better outcome .This has been validated in several studies36,54.  
 
Abraham et al in 1999 in a study of 29 patients from the same centre over a period  
 
 56
of 5 years had shown that hypertension , nephrotic proteinuria, and high Activity Index  
 
were predictive of progression to end stage renal failure in patients with diffuse  
 
proliferative lupus nephritis69. But that study had not looked into low albumin as a  
 
significant predictor for poor outcome and s.creatinine also failed to show any significant  
 
correlation.  
 
Creatinine clearance of </= 75ml/min was also a significant predictor of non  
 
responsiveness (p value =0.047) in the Univariate analysis, though s.creatinine of >/=  
 
1.5mg/dl did not show any significant correlation. This reflects the inadequacy of using  
 
s.creatinine as a surrogate marker for GFR77. 
 
 Notably, the parameters reflecting severity and chronicity of kidney disease in  
 
SLE like hypertension, hypoalbuminemia, proteinuria, low creatinine clearance and class  
 
IV renal histology , rather than the activity parameters like SLEDAI scores, serum anti- 
 
dsDNA antibodies, and complement concentrations at the entry time of the study  
 
correlated with nonresponsiveness to therapy. In our study therefore, systemic disease  
 
activity at the time of kidney biopsy did not show much value for the prediction of renal  
 
outcome in lupus nephritis. Several studies using different SLE activity indices at entry  
 
like the BILAG score by MacGowan et al39, ECLAM score by Houssiau et al54 have  
 
failed to show significant correlation with outcome of lupus nephritis. 
 
Majority of our patients (66.7%) had WHO class IV lupus followed by class II in  
 
21.8%. This is in keeping with the various studies like Mok CC et al in 1999 which  
 
showed 55%, NUH study in 2001 which showed 82%74.  
 
 Hypertension was the only parameter found to be highly significant in  
 
multivariate analysis as an independent  predictor of poor outcome in our study with a p  
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value of 0.002. This has been validated in several studies in India and the West. A study  
 
done by Fiehn et al in Germany published in 2003 among 56 patients showed that  
 
showed that histological signs of chronicity and either arterial hypertension or renal  
 
insufficiency, or both, were predictive for terminal renal failure62. We could not comment  
 
upon chronicity, as NIH scoring for activity / chronicity  in histology was not done in our  
 
study. 
 
Font et al studied prospectively 70 patients with lupus nephritis  and 70 age and  
 
sex matched controls with SLE but no evidence of nephropathy from 1988-1998. 
 
Compared to controls, lupus nephritis patients had a higher prevalence of hypertension  
 
(44% vs. 9%, p <0.001) at study entry and hypertension at onset was associated  
 
significantly (67% vs. 32%, p=0.01) with renal failure. This study also showed that  
 
hyperlipidaemia (78% vs. 27%, p<0.001) had significant association with development of  
 
renal failure.  
 
The markedly increased mortality in lupus nephritis from accelerated  
 
atherosclerosis mandates a higher state of vigilance in our SLE patients, and they must be  
 
monitored closely for symptoms and signs of cardiovascular disease. Primary prevention,  
 
by checking and treating hyperlipidaemia, hyperglycaemia and hypertension, counseling  
 
patients to stop smoking and exercise, and helping them to loose weight, is of paramount  
 
importance44. We however did not look into the risk association of hyperlipidaemia with  
 
outcomes in lupus nephritis in our cohort. Hypertension being a  comorbidity with several  
 
cardiovascular risk factors and the changing trend of premature cardiovascular morbidity  
 
and mortality in SLE, our finding of hypertension as the only predictor of  
 
snonresponsiveness to treatment should raise an alarm bell for ongoing silent  
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cardiovascular disease in patients with lupus nephritis. 
  
Though our study has failed to show any significant correlation of APLA with  
 
poor prognosis in lupus nephritis, Frampton et al. in a study published in 1991 have  
 
reported that 44% of lupus nephritis patients had antiphospholipid antibodies compared  
 
to 19.2% in our study. The presence of an associated antiphospholipid syndrome in SLE  
 
patients may contribute to the development of nephropathy, and represent a new factor  
 
related to mortality in lupus nephritis patients76. We would probably find such an  
 
association if our cohort of patients are followed up for a longer period of time. 
 
 The percentage of Responders in our study were 70.5% as against Non-  
 
responders who were 29.4% at the end of 6 months of follow up. In a study by Mark F et  
 
al. done on 82 patients with a 5 year follow up and published in 1996, only 45% patients  
 
had complete renal remission (defined  as normal sediment and excretion of <1 G protein  
 
per day) at the end of one year70. Our study had used the same definitions for outcome  
 
measures. It reflects the changing trend in lupus nephritis management over the past  
 
decade with better case finding, prompt initiation of immunosuppressive drugs and newer  
 
therapy. In the above study by Fiehn et al, in 2003 studied among 15 patients between  
 
1980-89 and 41 patients between 1990-99, the outcome of patients with newly diagnosed  
 
LN was significantly better between 1990 and 2000 than between 1980 and 1989. Kidney  
 
damage and chronic histological changes at time of diagnosis were significantly less  
 
common between 1990 and 2000, which is attributable to earlier diagnosis and treatment  
 
in the later decade62. 
 
The results of our study were similar to a study by Tak et al. done among 42  
 
patients with WHO class IV lupus and published in 2000 in which 81% of the patients  
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treated with Mycophenolate Mofetil had complete remission as against 76 percent treated  
 
with Cyclophosphamide and prednisolone followed by Azathioprine and prednisolone at  
 
the end of one year36.  But they had used a more stringent criteria with complete  
 
remission being defined as a value for urinary protein excretion that was less than 0.3g  
 
per 24 hours, with normal urinary sediments, a normal serum albumin concentration, and  
 
values for serum creatinine and creatinine clearance that were no more than 15 percent  
 
above the base-line value and also the outcomes were analyzed at the end of one year as  
 
against 6 months in our study36. Moreover, we did not have many patients on MMF for  
 
economical reasons, so as to compare with those figures. 
 
A study done by Gan et al in National University Hospital in Singapore among  
 
fifty patients in 2002 showed much similar rates of response compared to our study. It  
 
showed 44% patients were in complete remission, 26% in partial remission (thus  
 
responders were 70% similar to our finding) ; 34% had relapsed nephritis, 4% had  
 
chronic renal failure and 12% progressed to ESRD and there were five deaths over three  
 
years74. This further corroborates the fact that Asians have more severe lupus nephritis  
 
compared to their western counterparts10. 
 
In summary, our study shows expected demographic parameters of lupus  
 
nephritis in keeping with the literature, namely age, sex, histology type and clinical  
 
presentations4-9. The variables which were significant in the univariate analysis for a poor  
 
outcome of lupus nephritis were those reflecting chronicity and severity like  
 
hypoalbuminaemia, WHO class IV histology, hypertension, proteinuria and decreased  
 
creatinine clearance, rather than activity parameters. Hypertension, as the highly  
 
significant independent predictor of  poorer outcome by multivariate analysis is also  
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keeping with established literature.  
 
Higher prevalence of underlying premature and often silent, ongoing cardiovascular  
 
morbidity and mortality in SLE and association of  hypertension with chronicity,  
 
hyperlipidaemia, antiphospholipid syndrome and cardiovascular complications warrants  
 
these aspects to be looked into in future studies along with histological scoring for  
 
chronicity and activity. 
 
 
LIMITATIONS  of our study include short duration of follow up, humble sample size,  
 
genetic and geographic heterogeneity of our patients from different regions of the  
 
country, heterogeneity of treatment regimens, lack of NIH activity and chronicity indices  
 
in histology, lack of  lipid profiling and APLA in all patients.   
 
 
 
 
CONCLUSIONS  
 
 
 Seventy percent (55/78) patients of lupus nephritis were treatment responders.  
 
Significant predictors of poor outcome were Hypertension, WHO Class IV histology ,  
 
Creatnine clearance <75ml/min, S.albumin <3.5mg/dl, of which Hypertension was an  
 
independent predictor of poor outcome at the end of six months of therapy.  
 
Demographic pattern and the clinical presentation of lupus nephritis were in keeping with  
 
well established literature from India and elsewhere. 
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ANNEXURE B 
 
PROFORMA 
 
Name    Hosp No.   Sex  Age   
M/S    Place    Religion 
SLE: Time of diagnosis  Criteria for Diagnosis: 1/2/3/4/5/6/7/8/9/11/12 
Lupus Nephritis: Time of Dx   Criteria: 1/2/3/4/5/6/7  Class: 
 
 At Dx At 6 mts 
Hb   
TC   
Plts   
DCT   
ESR   
Urine RBCs   
Urine WBCs   
Casts   
24 hr UP   
Creat   
Urea   
Ds DNA   
Complement   
RF   
ANA   
Total Protein   
Albumin   
 
 
 
 
 
Rx: Steroids/ Cyclo/ Aza/ MMF    Outcome: CR/PR/NR/R/D 
        APLA: present/absent 
Co-morbidities:  HTN/ DM/ Hypothyroidism      
  
Infections: No. of Episodes        
      Sites:  
 
Side effects: 
 
Creat clearance:     
 
SLEDAI score:      Comments   
 1. At Dx- 
2. At 6mts- 
MASTER CHART 
 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
1 Ramasamy 35 13 No - - - - - Normal Normal Negative 83.5 99 0.84 84.34 83 83 Normal 
2 Velayutham 47 18 No - - - - - Normal Normal Negative 85.6 110.5 0.77 77.47 81 90 Normal 
3 Karuppathevar 53 44 Yes - - - - - Normal Normal Negative 86.8 113.7 0.76 76.34 87 89 Normal 
4 Muthiah 51 60 No - - - - - Normal Normal Negative 80.9 120 0.67 67.42 70 71 Stage I 
5 Venkatraman 52 18 No - - - - - Normal Normal Negative 89.1 109.9 0.81 81.07 87 86 Normal 
6 Suresh 34 15 No - - - - - Normal Normal Negative 83.4 109 0.77 76.51 85 82 Normal 
7 Chellam 44 40 Yes - - - - - Normal Normal Negative 84.1 109.6 0.77 76.73 85 84 Normal 
8 Naguppillai 62 24 No - - - - - Normal Normal Negative 86.7 111 0.78 78.11 83 84 Normal 
9 Raju 53 40 Yes - - - - - Normal Normal Negative 81.5 119.2 0.68 68.37 73 72 Stage I 
10 Kundan 72 64 No - - - - - Normal Normal Negative 77 74.3 1.04 103.6 84 82 Restrictive 
11 Rangasamy 51 28 No - - - - - Normal Normal Negative 89 106.4 0.84 83.65 80 84 Normal 
12 Jeyaram 63 48 No - - - - - Normal Normal Negative 80.9 118.3 0.68 68.39 75 74 Stage I 
13 Ramu 60 45 Yes - - - - - Normal Normal Negative 78.4 72.6 1.08 108 82 81 Restrictive 
14 Muthukrishnan 42 16 No - - - - - Normal Normal Negative 83.7 99.9 0.84 83.78 88 85 Normal 
15 Veeranan 47 40 Yes - - - - - Normal Normal Negative 80.5 118.6 0.68 67.88 71 70 Stage I 
16 Govindan 51 48 No - - - - - Normal Normal Negative 84.8 105.5 0.8 80.38 87 85 Normal 
17 Vailumuthu 39 18 No - - - - - Normal Normal Negative 85.6 108 0.79 79.26 86 81 Normal 
18 Sudarsanam 45 28 Yes - - - - - Normal Normal Negative 81.7 118.8 0.69 68.77 73 73 Stage I 
19 Ponniah 52 25 No - - - - - Normal Normal Negative 84.9 105.3 0.81 80.63 86 87 Normal 
20 Periyagoundar 60 36 Yes - - - - - Normal Normal Negative 52.4 92.4 0.57 56.71 71 73 Stage II 
21 Lakshmanan 58 28 No - - - - - Normal Normal Negative 84.8 106.6 0.8 79.55 83 80 Normal 
22 Dharmar 45 40 Yes - - - - - Normal Normal Negative 84.9 109.4 0.78 77.61 83 87 Normal 
23 Ramalingam 32 18 No - - - - - Normal Normal Negative 83 98 0.85 84.69 81 87 Normal 
24 Subramani 49 30 No - - - - - Normal Normal Negative 80.2 119.2 0.67 67.28 73 74 Stage I 
25 Vellaiyan 68 40 Yes - - - - - Normal Normal Negative 82.1 120 0.68 68.42 73 72 Stage I 
26 Mani 68 32 No - - - - - Normal Normal Negative 85.2 107.8 0.79 79.04 82 84 Normal 
27 Marisamy 56 36 No - - - - - Normal Normal Negative 81.9 119.4 0.69 68.59 75 74 Stage I 
28 Nalluthevar 53 24 Yes - - - - - Normal Normal Negative 83.9 99.9 0.84 83.98 85 81 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
29 Chinnian 45 18 No - - - - - Normal Normal Negative 85.4 111.3 0.77 76.73 81 81 Normal 
30 Ranganathan 33 22 Yes - - - - - Normal Normal Negative 88.4 108 0.82 81.85 86 83 Normal 
31 Krishnamoorthi 58 44 No - - - - - Normal Normal Negative 85.1 111.6 0.76 76.25 90 84 Normal 
32 Varadhan 57 36 No - - - - - Normal Normal Negative 83.4 100.5 0.83 82.99 82 87 Normal 
33 Abraham 59 64 No - - - - - Normal Normal Negative 76.3 70.5 1.08 108.2 84 88 Restrictive 
34 Balusamy 62 44 Yes - - - - - Normal Normal Negative 85.9 109.6 0.78 78.38 83 80 Normal 
35 Arockiasamy 52 40 Yes - - - - - Normal Normal Negative 85.3 110.5 0.77 77.19 90 85 Normal 
36 Mujibur 58 21 No - - - - - Normal Normal Negative 84.8 106.6 0.8 79.55 83 80 Normal 
37 Thomas 59 33 Yes - - - - - Normal Normal Negative 81.5 116.9 0.7 69.72 75 72 Stage I 
38 Seeni 35 36 Yes - - - - - Normal Normal Negative 64.3 109.5 0.59 58.72 71 72 Stage II 
39 Kuttiyappan 41 30 No - - - - - Normal Normal Negative 84.7 107.4 0.79 78.86 88 82 Normal 
40 Abdullah 49 32 Yes - - - - - Normal Normal Negative 77.3 72.9 1.06 106 84 87 Restrictive 
41 Micheal 52 30 No - - - - - Normal Normal Negative 83.6 101.5 0.82 82.36 88 83 Normal 
42 Loganathan 57 50 No - - - - - Normal Normal Negative 75.9 73.4 1.03 103.4 88 87 Mixed 
43 Kannuchamy 61 44 Yes - - - - - Normal Normal Negative 83.2 99.9 0.83 83.28 88 89 Normal 
44 Joseph 55 45 No - - - - - Normal Normal Negative 80.7 116.2 0.69 69.45 74 75 Stage I 
45 Kannuthevar 31 26 No - - - - - Normal Normal Negative 88.1 114.4 0.77 77.01 88 80 Normal 
46 Subbunadar 36 30 No - - - - - Normal Normal Negative 86.5 115.3 0.75 75.02 82 85 Normal 
47 Arulraj 43 16 No - - - - - Normal Normal Negative 86.3 112.7 0.77 76.57 84 87 Normal 
48 Veeran 54 28 Yes - - - - - Normal Normal Negative 84.3 105.2 0.8 80.13 87 85 Normal 
49 Lakshmanan 56 40 Yes - - - - - Normal Normal Negative 87.1 118.2 0.74 73.69 84 90 Normal 
50 Usman 65 36 Yes - - - - - Normal Normal Negative 81.4 119.3 0.68 68.23 75 75 Stage I 
51 Kasi Viswanathan 36 30 Yes - - - - - Normal Normal Negative 83.7 104.5 0.8 80.1 82 88 Normal 
52 Logu 46 28 No - - - - - Normal Normal Negative 86.5 115.3 0.75 75.02 82 85 Normal 
53 Kannan 41 36 No - - - - - Normal Normal Negative 89.4 113.4 0.79 78.84 86 87 Normal 
54 Seenithevar 59 20 Yes - - - - - Normal Normal Negative 84.9 104.4 0.81 81.32 83 82 Normal 
55 Palani 52 36 No - - - - - Normal Normal Negative 83.6 102.1 0.82 81.88 85 90 Normal 
56 Singaram 62 48 No - - - - - Normal Normal Negative 84.7 109.4 0.77 77.42 88 87 Normal 
57 Dennis 64 30 No - - - - - Normal Normal Negative 83.8 103.3 0.81 81.12 85 86 Normal 
58 Arunachalam 54 15 Yes - - - - - Normal Normal Negative 83.7 101.1 0.83 82.79 90 84 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
59 Vellaisamy 59 28 No - - - - - Normal Normal Negative 84.2 111 0.76 75.86 87 81 Normal 
60 Peer Muhamed 65 32 No - - - - - Normal Normal Negative 89.9 113.2 0.79 79.42 83 81 Normal 
61 Subburaj 62 18 No - - - - - Normal Normal Negative 88 105.5 0.83 83.41 87 90 Normal 
62 Narayanan 41 32 No - - - - - Normal Normal Negative 85 111.8 0.76 76.03 87 86 Normal 
63 Thiruppathi 47 20 Yes - - - - - Normal Normal Negative 83.7 100.6 0.83 83.2 86 90 Normal 
64 Williams 34 22 No - - - - - Normal Normal Negative 86.7 109.9 0.79 78.89 88 81 Normal 
65 Palavesam 47 20 No - - - - - Normal Normal Negative 83.7 100.6 0.83 83.2 86 90 Normal 
66 Yousuf 55 32 No - - - - - Normal Normal Negative 85.5 109.3 0.78 78.23 88 83 Normal 
67 Panneer 65 15 Yes - - - - - Normal Normal Negative 84.4 107.2 0.79 78.73 81 84 Normal 
68 Nataraj 64 55 No - - - - - Normal Normal Negative 59 104 0.57 56.73 70 71 Stage II 
69 Martin 32 16 No - - - - - Normal Normal Negative 84.1 105 0.8 80.1 87 86 Normal 
70 Maruthu 44 12 Yes - - - - - Normal Normal Negative 89.2 112.8 0.79 79.08 83 90 Normal 
71 Abbas 60 44 Yes - - - - - Normal Normal Negative 80.7 116.2 0.69 69.45 74 75 Stage I 
72 Chinnamani 41 18 No - - - - - Normal Normal Negative 84.8 106.6 0.8 79.55 83 80 Normal 
73 David 51 32 Yes - - - - - Normal Normal Negative 84.6 106 0.8 79.81 88 86 Normal 
74 Anbarasan 35 12 No - - - - - Normal Normal Negative 87.6 115 0.76 76.17 80 82 Normal 
75 Periyasamy 46 36 Yes - - - - - Normal Normal Negative 85.9 109.9 0.78 78.16 84 89 Normal 
76 Natharshah 32 19 No - - - - - Normal Normal Negative 83.9 106 0.79 79.15 89 85 Normal 
77 Maruthanayagam 42 15 No - - - - - Normal Normal Negative 85.6 110.3 0.78 77.61 82 82 Normal 
78 Innasi 55 50 Yes - - - - - Normal Normal Negative 80.1 116.2 0.69 68.93 75 74 Stage I 
79 Pasupathy 43 32 No - - - - - Normal Normal Negative 83.1 98.4 0.84 84.45 82 83 Normal 
80 Rajkumar 58 36 No - - - - - Normal Normal Negative 87.7 116.4 0.75 75.34 89 80 Normal 
81 Marthandam 54 32 Yes - - - - - Normal Normal Negative 85.9 105.3 0.82 81.58 85 82 Normal 
82 Dharmalingam 45 22 No - - - - - Normal Normal Negative 84.3 106.7 0.79 79.01 86 84 Normal 
83 Prakash 54 27 No - - - - - Normal Normal Negative 86 104.3 0.82 82.45 80 84 Normal 
84 Nesamani 31 14 No - - - - - Normal Normal Negative 85.4 105 0.81 81.33 82 90 Normal 
85 Chandran 55 26 No - - - - - Normal Normal Negative 85.2 110.6 0.77 77.03 81 83 Normal 
86 Palavendran 58 60 Yes - - - - - Normal Normal Negative 78.9 74.2 1.06 106.3 85 86 Mixed 
87 Sekaran 58 48 No - - - - - Normal Normal Negative 81.2 118.9 0.68 68.29 72 71 Stage I 
88 Natarajan 62 20 No - - - - - Normal Normal Negative 83.9 102.5 0.82 81.85 85 86 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
89 Issac 43 12 No - - - - - Normal Normal Negative 83.9 99.3 0.84 84.49 88 81 Normal 
90 Thanasekaran 52 30 Yes - - - - - Normal Normal Negative 84.5 106.9 0.79 79.05 80 88 Normal 
91 Annamalai 59 52 No - - - - - Normal Normal Negative 87.7 116.6 0.75 75.21 89 82 Normal 
92 Saravanan 39 14 No - - - - - Normal Normal Negative 87.6 111 0.79 78.92 85 81 Normal 
93 Rajagopalan 42 32 Yes - - - - - Normal Normal Negative 81.6 118.4 0.69 68.92 75 74 Stage I 
94 Namasivayam 57 39 No - - - - - Normal Normal Negative 82.4 118.2 0.7 69.71 71 73 Stage I 
95 Ibrahim 34 22 Yes - - - - - Normal Normal Negative 82.9 117.3 0.71 70.67 73 74 Stage I 
96 Kamarajan 64 21 Yes - - - - - Normal Normal Negative 80.5 117.4 0.69 68.57 72 74 Stage I 
97 Thandapani 41 24 No - - - - - Normal Normal Negative 86.2 114.2 0.75 75.48 85 84 Normal 
98 Pakker Mohamed 57 48 No - - - - - Normal Normal Negative 81.3 120 0.68 67.75 73 74 Stage I 
99 Dhanapal 35 15 No - - - - - Normal Normal Negative 84.7 112 0.76 75.63 90 82 Normal 
100 Amalraj 59 44 Yes - - - - - Normal Normal Negative 82.4 118.2 0.7 69.71 71 73 Stage I 
101 Mahalingam 41 32 No - - - - - Normal Normal Negative 85 111.8 0.76 76.03 87 86 Normal 
102 Sundarraj 59 44 No - - - - - Normal Normal Negative 66.6 110.1 0.6 60.49 72 71 Stage II 
103 Fulgunan 47 28 No - - - - - Normal Normal Negative 87.5 107.5 0.81 81.4 84 83 Normal 
104 Rajendraprasad 38 22 No - - - - - Normal Normal Negative 86.2 103 0.84 83.69 83 85 Normal 
105 Senthilkumar 53 48 No - - - - - Normal Normal Negative 88 114.3 0.77 76.99 82 90 Normal 
106 Rahamadulla 50 40 No - - - - - Normal Normal Negative 81.5 116.9 0.7 69.72 75 72 Stage I 
107 Chakravarthi 59 60 No - - - - - Normal Normal Negative 80.6 118.4 0.68 68.07 74 75 Stage I 
108 Nazirudin 46 12 No - - - - - Normal Normal Negative 84.7 102.4 0.83 82.71 83 81 Normal 
109 Govindaraj 33 25 Yes - - - - - Normal Normal Negative 82.2 113.9 0.72 72.17 75 73 Stage I 
110 Sarathy 64 55 No - - - - - Normal Normal Negative 80.2 116.2 0.69 69.02 74 73 Stage I 
111 Nizam Ali 60 20 No - - - - - Normal Normal Negative 83.1 98.4 0.84 84.45 88 80 Normal 
112 Seeni Rowthar 37 11 No - - - - - Normal Normal Negative 83.9 99 0.85 84.75 90 86 Normal 
113 Arockiaraj 48 11 No - - - - - Normal Normal Negative 83.2 100.1 0.83 83.12 87 88 Normal 
114 Jeyapaul 62 36 No - - - - - Normal Normal Negative 81.7 119.4 0.68 68.43 74 75 Stage I 
115 Sethuraman 42 28 No - - - - - Normal Normal Negative 88.3 104.7 0.84 84.34 85 89 Normal 
116 Bhaskaran 65 36 No - - - - - Normal Normal Negative 83.4 100.5 0.83 82.99 82 87 Normal 
117 Karuppanan 32 16 Yes - - - - - Normal Normal Negative 84.1 106 0.79 79.34 80 87 Normal 
118 Santhakumar 63 24 No - - - - - Normal Normal Negative 84.2 108.6 0.78 77.53 81 80 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
119 Loganathan 65 25 No - - - - - Normal Normal Negative 84.6 104 0.81 81.35 84 83 Normal 
120 Rahimbai 42 24 No - - - - - Normal Normal Negative 80.3 119 0.67 67.48 74 75 Stage I 
121 Muniandi 39 24 No - - - - - Normal Normal Negative 85.7 101 0.85 84.85 84 86 Normal 
122 Jhonson 64 29 No - - - - - Normal Normal Negative 84.1 107.5 0.78 78.23 82 80 Normal 
123 Parthasarathy 62 40 Yes - - - - - Normal Normal Negative 87.6 112.8 0.78 77.66 86 88 Normal 
124 Gurusamy 51 64 No - - - - - Normal Normal Negative 86.3 112.7 0.77 76.57 84 87 Normal 
125 Chinnamani 61 60 No - - - - - Normal Normal Negative 67 108.3 0.62 61.87 71 73 Stage II 
126 Soundararajan 31 16 No - - - - - Normal Normal Negative 84.6 108 0.78 78.33 80 86 Normal 
127 Balaji 33 12 No - - - - - Normal Normal Negative 85.2 103 0.83 82.72 81 83 Normal 
128 Muraldharan 48 36 Yes - - - - - Normal Normal Negative 55.7 96.4 0.58 57.78 71 72 Stage II 
129 Panneerselvam 54 28 No - - - - - Normal Normal Negative 86.4 115.2 0.75 75 81 87 Normal 
130 Nagaraja 31 16 No - - - - - Normal Normal Negative 89.6 118.2 0.76 75.8 85 87 Normal 
131 Jegadeesan 58 30 No - - - - - Normal Normal Negative 87.6 116.6 0.75 75.13 80 80 Normal 
132 Pandiaraj 53 24 Yes - - - - - Normal Normal Negative 85.6 114 0.75 75.09 81 86 Normal 
133 Rajappan 64 28 No - - - - - Normal Normal Negative 80.7 118 0.68 68.39 75 74 Stage I 
134 Kunjappan 51 24 No - - - - - Normal Normal Negative 85.4 100.8 0.85 84.72 85 88 Normal 
135 Vadivel 57 30 No - - - - - Normal Normal Negative 88.1 114.4 0.77 77.01 88 80 Normal 
136 Jacob 65 50 No - - - - - Normal Normal Negative 79 72.4 1.09 109.1 89 91 Mixed 
137 Balu 55 24 No - - - - - Normal Normal Negative 88.2 114.3 0.77 77.17 83 89 Normal 
138 Ravindran 61 21 No - - - - - Normal Normal Negative 83.4 104.9 0.8 79.5 86 85 Normal 
139 Sangu Goundar 37 12 Yes - - - - - Normal Normal Negative 84.9 111 0.76 76.49 85 81 Stage I 
140 Thanikachalam 63 28 No - - - - - Normal Normal Negative 86.7 114 0.76 76.05 86 89 Normal 
141 Cherian 59 33 No - - - - - Normal Normal Negative 53.5 94.8 0.56 56.43 73 72 Stage II 
142 Anandan 31 24 No - - - - - Normal Normal Negative 85.4 117 0.73 72.99 84 90 Normal 
143 Veerabahu 64 42 No - - - - - Normal Normal Negative 87.4 112 0.78 78.04 87 88 Normal 
144 Duraisamy 52 30 No - - - - - Normal Normal Negative 84.7 109.4 0.77 77.42 80 82 Normal 
145 Rajangam 40 18 Yes - - - - - Normal Normal Negative 83 109 0.76 76.15 84 85 Normal 
146 Sudalaiandi 65 48 Yes - - - - - Normal Normal Negative 81.1 119.5 0.68 67.87 73 72 Stage I 
147 Thiagarajan 48 30 No - - - - - Normal Normal Negative 80.1 119.7 0.67 66.92 74 73 Stage I 
148 Vincent 65 33 No - - - - - Normal Normal Negative 85.6 110.3 0.78 77.61 82 82 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
149 Kumaraguru 58 20 Yes - - - - - Normal Normal Negative 86.4 110 0.79 78.55 81 87 Normal 
150 Bangaru 32 20 No - - - - - Normal Normal Negative 85.1 106 0.8 80.28 86 83 Normal 
151 Rajendran 45 Nil No - - - - - Normal Normal Negative 84.2 115.2 0.84
84.3
4 83 83 Normal 
152 Vellaisamy 38 Nil No - - - - - Normal Normal Negative 85.6 110.5 0.77
77.4
7 81 90 Normal 
153 Subburajan 72 Nil No - - - - - Normal Normal Negative 86.8 113.7 0.76
76.3
4 87 89 Normal 
154 Mookkandi 57 Nil No - - - - - Normal Normal Negative 80.9 120 0.67
67.4
2 70 71 Normal 
155 Nallusamy 64 Nil Yes - - - - - Normal Normal Negative 89.1 109.9 0.81
81.0
7 87 86 Normal 
156 James 70 Nil No - - - - - Normal Normal Negative 83.4 109 0.77
76.5
1 85 82 Normal 
157 Fakrudheen 43 Nil No - - - - - Normal Normal Negative 84.1 109.6 0.77
76.7
3 85 84 Normal 
158 Palavesakonar 39 Nil No - - - - - Normal Normal Negative 86.7 111 0.78
78.1
1 83 84 Normal 
159 Babulal 54 Nil No - - - - - Normal Normal Negative 81.5 119.2 0.68
68.3
7 73 72 Normal 
160 Rangegoundar 67 Nil No - - - - - Normal Normal Negative 77 74.3 1.04
103.
63 84 82 Normal 
161 Arockiam 59 Nil No - - - - - Normal Normal Negative 89 106.4 0.84
83.6
5 80 84 Normal 
162 Thangadurai 48 Nil No - - - - - Normal Normal Negative 80.9 118.3 0.68
68.3
9 75 74 Normal 
163 Sridharan 64 Nil No - - - - - Normal Normal Negative 78.4 72.6 1.08
107.
99 82 81 Normal 
164 Rangannan 71 Nil No - - - - - Normal Normal Negative 83.7 99.9 0.84
83.7
8 88 85 Normal 
165 Krishnan 52 Nil No - - - - - Normal Normal Negative 80.5 118.6 0.68
67.8
8 71 70 Normal 
166 Rajarathinam 61 Nil No - - - - - Normal Normal Negative 84.8 105.5 0.80
80.3
8 87 85 Normal 
167 Chokkanathan 48 Nil Yes - - - - - Normal Normal Negative 85.6 108 0.79 79.2 86 81 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
6 
168 Williams 57 Nil No - - - - - Normal Normal Negative 81.7 118.8 0.69
68.7
7 73 73 Normal 
169 Dhandapani 60 Nil No - - - - - Normal Normal Negative 84.9 105.3 0.81
80.6
3 86 87 Normal 
170 Karuppan 45 Nil No - - - - - Normal Normal Negative 52.4 92.4 0.57
56.7
1 71 73 Normal 
171 Robert 74 Nil No - - - - - Normal Normal Negative 84.8 106.6 0.80
79.5
5 83 80 Normal 
172 Ismail 47 Nil No - - - - - Normal Normal Negative 84.9 109.4 0.78
77.6
1 83 87 Stage I 
173 Raju 72 Nil Yes - - - - - Normal Normal Negative 83 98 0.85
84.6
9 81 87 Normal 
174 Malleswaran 53 Nil No - - - - - Normal Normal Negative 80.2 119.2 0.67
67.2
8 73 74 Normal 
175 Surianarayanan 68 Nil No - - - - - Normal Normal Negative 82.1 120 0.68
68.4
2 73 72 Normal 
176 Venkatraj 52 Nil Yes - - - - - Normal Normal Negative 85.2 107.8 0.79
79.0
4 82 84 Normal 
177 Manickam 48 Nil No - - - - - Normal Normal Negative 81.9 119.4 0.69
68.5
9 75 74 Normal 
178 Prakasam 56 Nil No - - - - - Normal Normal Negative 83.9 99.9 0.84
83.9
8 85 81 Normal 
179 Thirumal 60 Nil No - - - - - Normal Normal Negative 85.4 111.3 0.77
76.7
3 81 81 Normal 
180 Subbanna 55 Nil No - - - - - Normal Normal Negative 88.4 108 0.82
81.8
5 86 83 Normal 
181 Babuji 42 Nil No - - - - - Normal Normal Negative 85.1 111.6 0.76
76.2
5 90 84 Normal 
182 Velu 37 Nil No - - - - - Normal Normal Negative 83.4 100.5 0.83
82.9
9 82 87 Normal 
183 Duraiappan 42 Nil No - - - - - Normal Normal Negative 76.3 70.5 1.08
108.
23 84 88 Normal 
184 Jeevanandham 35 Nil No - - - - - Normal Normal Negative 85.9 109.6 0.78
78.3
8 83 80 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
185 Madhavan 59 Nil No - - - - - Normal Normal Negative 85.3 110.5 0.77
77.1
9 90 85 Normal 
186 Chandrasekaran 69 Nil No - - - - - Normal Normal Negative 84.8 106.6 0.80
79.5
5 83 80 Normal 
187 Varadarajan 67 Nil No - - - - - Normal Normal Negative 81.5 116.9 0.70
69.7
2 75 72 Normal 
188 Joel 42 Nil No - - - - - Normal Normal Negative 64.3 109.5 0.59
58.7
2 71 72 Normal 
189 Mohemmad 38 Nil No - - - - - Normal Normal Negative 84.7 107.4 0.79
78.8
6 88 82 Normal 
190 Punniakodi 51 Nil No - - - - - Normal Normal Negative 77.3 72.9 1.06
106.
04 84 87 Normal 
191 Sitaraman 46 Nil No - - - - - Normal Normal Negative 83.6 101.5 0.82
82.3
6 88 83 Normal 
192 Ilango 62 Nil No - - - - - Normal Normal Negative 75.9 73.4 1.03
103.
41 88 87 Normal 
193 Dharmarajan 39 Nil No - - - - - Normal Normal Negative 83.2 99.9 0.83
83.2
8 88 89 Normal 
194 Packianathan 44 Nil No - - - - - Normal Normal Negative 80.7 116.2 0.69
69.4
5 74 75 Normal 
195 Arunagiri 57 Nil No - - - - - Normal Normal Negative 88.1 114.4 0.77
77.0
1 88 80 Normal 
196 Paranjothy 53 Nil No - - - - - Normal Normal Negative 86.5 115.3 0.75
75.0
2 82 85 Normal 
197 Innasi Goundar 48 Nil Yes - - - - - Normal Normal Negative 86.3 112.7 0.77
76.5
7 84 87 Normal 
198 Deenadayalan 37 Nil No - - - - - Normal Normal Negative 84.3 105.2 0.80
80.1
3 87 85 Normal 
199 Venkoban 54 Nil No - - - - - Normal Normal Negative 87.1 118.2 0.74
73.6
9 84 90 Normal 
200 Francis 61 Nil No - - - - - Normal Normal Negative 81.4 119.3 0.68
68.2
3 75 75 Normal 
 
 
